Profile data is unavailable for this security.
About the company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. It is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). It has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).
- Revenue in USD (TTM)0.00
- Net income in USD-35.87m
- Incorporated2004
- Employees12.00
- LocationEledon Pharmaceuticals Inc19900 Macarthur Blvd Ste 550IRVINE 92612-8426United StatesUSA
- Phone+1 (949) 238-8090
- Fax+1 (302) 655-5049
- Websitehttps://eledon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals Inc | 1.00m | -50.59m | 38.42m | 41.00 | -- | 0.2583 | -- | 38.42 | -2.01 | -2.01 | 0.0397 | 5.89 | 0.0056 | -- | -- | 24,390.24 | -28.43 | -- | -29.64 | -- | -- | -- | -5,059.40 | -- | -- | -- | 0.00 | -- | -- | -- | -70.88 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -19.08m | 39.02m | 24.00 | -- | 0.7603 | -- | -- | -1.82 | -1.82 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -38.45 | -109.37 | -39.70 | -164.49 | -- | -- | -- | -8,458.02 | -- | -- | 0.00 | -- | -- | -- | -69.64 | -- | -0.3086 | -- |
| Global Internet of People Inc | 22.12m | 8.40m | 41.21m | 96.00 | 4.73 | 0.6807 | 4.04 | 1.86 | 0.3554 | 0.3554 | 0.9556 | 2.47 | 0.5001 | 1.70 | 2.19 | 230,381.00 | 18.76 | -- | 20.11 | -- | 80.31 | -- | 37.51 | -- | 17.72 | 13.40 | -- | -- | 29.32 | -- | 24.02 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 0.00 | -24.53m | 41.77m | 61.00 | -- | 1.29 | -- | -- | -1.29 | -1.29 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -94.12 | -- | -114.43 | -- | -- | -- | -- | -- | -- | -- | 0.1021 | -- | -- | -- | -63.35 | -- | -- | -- |
| Connect Biopharma Holdings Ltd (ADR) | -100.00bn | -100.00bn | 42.41m | 108.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -67.71 | -- | -- | -- |
| Neximmune Inc | 0.00 | -57.38m | 42.71m | 74.00 | -- | 0.6068 | -- | -- | -2.53 | -2.53 | 0.00 | 3.08 | 0.00 | -- | -- | 0.00 | -56.01 | -- | -59.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.70 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -35.87m | 42.78m | 12.00 | -- | 0.2737 | -- | -- | -2.44 | -2.44 | 0.00 | 11.36 | 0.00 | -- | -- | 0.00 | -20.32 | -29.03 | -20.74 | -30.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.27 | -- | -- | -- |
| Psycheceutical Bioscience Inc | 1.16m | -149.52k | 42.90m | 28.00 | -- | 0.7646 | -- | 37.08 | -0.1157 | -0.1157 | 0.8953 | 0.3399 | 0.6308 | 98.60 | 2.34 | 41,318.93 | -8.15 | -19.61 | -29.82 | -55.36 | 60.50 | 39.98 | -12.92 | -43.93 | 0.959 | -- | 0.0906 | -- | -30.52 | 83.37 | 43.79 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -12.73m | 43.45m | 4.00 | -- | 1.37 | -- | -- | -2.15 | -2.15 | 0.00 | 4.65 | 0.00 | -- | -- | 0.00 | -52.30 | -- | -54.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.65 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 24.13m | -97.48m | 43.62m | 124.00 | -- | 0.6951 | -- | 1.81 | -1.55 | -1.55 | 0.3833 | 0.9991 | 0.1169 | -- | 8.31 | 194,580.60 | -47.24 | -52.85 | -54.49 | -62.36 | -- | -- | -404.00 | -828.85 | -- | -- | 0.3936 | -- | 55.62 | 136.57 | -3.00 | -- | -11.72 | -- |
| Mink Therapeutics Inc | 0.00 | -34.14m | 43.96m | 33.00 | -- | 2.54 | -- | -- | -1.73 | -1.73 | 0.00 | 0.5157 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.84 | 0.00 | -- | -- | -- | -86.05 | -- | -- | -- |
| Avalon Globocare Corp | 1.40m | -8.79m | 44.89m | 5.00 | -- | 34.92 | -- | 32.09 | -0.1021 | -0.1021 | 0.0162 | 0.0145 | 0.1335 | -- | 41.42 | 279,764.00 | -83.94 | -96.37 | -139.78 | -126.28 | 30.08 | 25.60 | -628.67 | -746.84 | -- | -34.64 | 0.7168 | -- | 0.9588 | 17.67 | 28.31 | -- | -47.54 | -- |
| Sera Prognostics Inc | 107.00k | -40.86m | 45.78m | 115.00 | -- | 0.3595 | -- | 427.88 | -1.34 | -1.34 | 0.0035 | 4.12 | 0.0011 | -- | 4.55 | 930.43 | -41.35 | -- | -43.71 | -- | 51.40 | -- | -38,185.05 | -- | -- | -186.86 | 0.0083 | -- | 228.00 | -- | -76.39 | -- | -- | -- |
| Team, Inc. | 898.51m | -184.19m | 47.00m | 5.20k | -- | 1.74 | -- | 0.0523 | -5.75 | -5.75 | 27.49 | 0.6278 | 1.24 | 18.42 | 4.41 | 172,790.60 | -25.37 | -13.47 | -32.81 | -15.99 | 25.13 | 26.59 | -20.50 | -11.80 | 1.83 | -0.7087 | 0.944 | -- | 2.58 | -6.08 | 23.91 | -- | -17.41 | -- |
Data as of May 25 2022. Currency figures normalised to Eledon Pharmaceuticals Inc's reporting currency: US Dollar USD
47.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2022 | 2.33m | 16.26% |
| Cormorant Asset Management LPas of 31 Mar 2022 | 1.31m | 9.12% |
| The Vanguard Group, Inc.as of 31 Mar 2022 | 674.21k | 4.71% |
| Woodline Partners LPas of 31 Mar 2022 | 673.14k | 4.71% |
| Point72 Asset Management LPas of 31 Mar 2022 | 555.90k | 3.89% |
| Medical Strategy GmbHas of 31 Jan 2022 | 375.60k | 2.63% |
| Ikarian Capital LLCas of 31 Mar 2022 | 362.54k | 2.53% |
| CM Management LLCas of 31 Mar 2022 | 225.00k | 1.57% |
| Geode Capital Management LLCas of 31 Mar 2022 | 126.71k | 0.89% |
| Eversept Partners LPas of 31 Mar 2022 | 114.01k | 0.80% |
More ▼
Data from 31 Jan 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
